TORONTO, May 19 /CNW/ - Spectral Diagnostics Inc., (TSX:SDI), a Phase III company developing the first theranostic treatment for
septic shock, today announced that Dr. Paul Walker, the Company's
President and Chief Executive Officer, will present at BioFinance 2011
on Wednesday, June 1, at 10:15 a.m. Eastern Time. The conference will
be held at the St. Andrew's Club & Conference Centre in Toronto,
Dr. Walker will provide a corporate update, including information about
the Company's pivotal sepsis program.
BioFinance is a prominent Canadian investor conference for the life
sciences industry. The two-day event brings together key industry
players interested in investment opportunities and issues affecting
companies in the life sciences sector. Presenting companies span a
range of industries including biologics, medical devices, drug
delivery, vaccines, and diagnostics.
About Spectral Diagnostics
Spectral is a Phase III company seeking U.S. FDA approval for its lead
theranostics product for the treatment of patients with septic shock.
Toraymyxin is a therapeutic hemoperfusion device that removes
endotoxin, which can cause sepsis, from the bloodstream. Directed by
the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared
diagnostic for the risk of developing sepsis, Spectral's EUPHRATES
trial is the world's first theranostics trial in the area of sepsis.
Toraymyxin has been approved for therapeutic use in 18 countries, and
has been used safely and effectively in more than 80,000 patients to
date. In March, 2009, Spectral obtained the exclusive development and
commercial rights in the U.S. for Toraymyxin, and in November, 2010,
signed an exclusive distribution agreement for this product in Canada.
More than 250,000 patients are diagnosed with severe sepsis and septic
shock in North America each year, representing a greater than $1
billion market opportunity for Spectral. Spectral is listed on the
Toronto Stock Exchange under the symbol SDI.
For further information please visit www.spectraldx.com
SOURCE Spectral Diagnostics Inc.
For further information:
| Anthony Businskas |
Executive Vice President and CFO
416-626-3233 ext. 2200
| Adam Peeler |
416-815-0700 ext. 225